KeyBanc Capital Markets Adjusts Price Target on Codex DNA to $5 From $8, Maintains Overweight Rating
MT NewswiresNov 9, 2022 22:45
Codex DNA Analyst Ratings
Benzinga Analyst RatingsNov 9, 2022 17:51
Keybanc Maintains Overweight on Codex DNA, Lowers Price Target to $5
Benzinga Real-time NewsNov 9, 2022 17:50
No Data
No Data